AI주식인사이트AI Stock Insight
C

인벤티지랩

389470KOSDAQ

44.5 / 100

Reference Date: 2026-10-23

Financial Score15.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 1.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

InventiZ Lab is a DDS (Drug Delivery System) platform company leveraging microfluidics-based Laminar-FLUIDigm™ technology to develop long-acting injectables and gene delivery solutions. It utilizes the IVL-DrugFluidic® platform for improved new drug development and the IVL-GeneFluidic® platform for LNP formulation services for mRNA vaccines, alongside expanding CDMO (Contract Development and Manufacturing Organization) operations. The company currently produces and sells Durahart SR-3 injectable solution and is advancing multiple drug candidates, including IVL3001, IVL3003, and IVL3004, through various clinical trials.

Number of Employees

73people

Average Salary

44.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
4.09Industry Average 1.200.0Point

3.4x industry avg (risky)

ROE
-28.06Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
12.37Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲117.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼34.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -91.6% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 24,850Won52-week high 99,50052-week low 23,700
1-month return3.0Point

1m 1.43% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral전환주식의전환가액조정 (전환우선주)2026-10-19